
PTC Therapeutics (PTCT) Stock Forecast & Price Target
PTC Therapeutics (PTCT) Analyst Ratings
Bulls say
PTC Therapeutics is benefiting from a powerful commercial inflection, as Sephience sales of $181.9MM beat consensus and drove Q3 total revenue to $357.8MM, while FY2026 product revenue guidance was raised to $960MM-$990MM and total revenue guidance to $1.29B-$1.32B. The launch appears durable and broadening, with over 2,000 active patients worldwide, ~90% renewal rates, increasing switch uptake, and continued geographic expansion across the U.S., EU, Japan, and other markets, supporting management’s view that Sephience could ultimately become a $2B+ product. Beyond PKU, the company has additional upside from a well-capitalized balance sheet with $2.13B in cash and a deep pipeline, including ST-920 with a rolling BLA expected in Q4:26, votoplam, and earlier-stage programs that can extend growth.
Bears say
PTC Therapeutics is pressured by weakening legacy revenue streams, with Emflaza Q3 sales of $25.1MM still down 28.7% Y/Y and expected 2026 sales of $87.6MM, down 40% Y/Y, while low-price generic erosion and competition continue to weigh on its DMD franchise. Its regulatory profile is also deteriorating: Translarna lost EU market authorization in March 2025, and vatiquinone received a CRL on August 19, 2025 after the FDA said the efficacy package was insufficient, forcing additional studies and delaying any resubmission path. With substantial international exposure, persistent clinical-trial risk, and uncertainty around pipeline conversion, the company faces a difficult outlook if newer assets fail to offset declining commercial products.
This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction
Start investing in PTC Therapeutics (PTCT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PTC Therapeutics (PTCT) Forecast
PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction
Start investing in PTC Therapeutics (PTCT)
Order type
Buy in
Order amount
Est. shares
0 shares